Horizon Discovery inks subscription-based licensing deal

Horizon Discovery has inked a subscription-based licensing deal for its biomanufacturing cell lines. The deal, the first of its type for the company and with an unnamed commercial partner, is worth a minimum of £500,000.

"We look forward to making further announcements in this area as Horizon continues its momentum as a key player in the bioproduction space," said chief executive Darrin Disley.

"This new announcement further validates our approach, with our Partner demonstrating their confidence by making a five year commitment via subscription model to the programme."